

underwent endoscopic transsphenoidal surgery 7 years later, which was complicated by panhypopituitarism and cranial diabetes insipidus. Postoperatively, CD was cured, with the resolution of her metabolic comorbidities.

CONCLUSION

Despite the increasing prevalence of T2D in adolescents, clinicians must recognize the diagnostic challenge of CD in this age group. Atypical manifestations in a presumed T2D patient should prompt consideration of Cushing's syndrome.

EP_A058

INSULIN-RECALCITRANT HYPERGLYCEMIA FOLLOWING CAPIVASERTIB THERAPY: A NOVEL CHALLENGE IN A NON-DIABETIC PATIENT

Jun Yang Tan¹ and Waye Hann Kang¹

¹Department of Medicine, M. Kandiah Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman

INTRODUCTION

Capivasertib is a selective oral AKT inhibitor approved for hormone receptor-positive, HER2-negative advanced breast cancer with AKT pathway mutations. As AKT is integral to insulin signaling, its inhibition predisposes patients to hyperglycemia. We report a case of severe capivasertib-induced hyperglycemia with profound insulin resistance in a non-diabetic patient.

CASE

A 56-year-old female with metastatic breast cancer (ER/PR-positive, HER2-negative, AKT1- and ESR1-mutated, TMB-high) presented with severe hyperglycemia following capivasertib initiation. She had no prior diabetes history, with a baseline hemoglobin A1c of 5.6%. Her first cycle (200 mg twice daily, 7 April 2025) was uncomplicated metabolically. The second cycle was escalated to 400 mg twice daily on 21 April 2025. By Day 3, blood glucose rose significantly. Premixed insulin 20 units failed to achieve glycemic control, necessitating intravenous insulin infusion. Despite escalation to 30 units per hour, euglycemia could not be achieved. Notably, there was no biochemical evidence of diabetic ketoacidosis or hyperosmolar hyperglycemic state, and the patient remained hemodynamically stable. No corticosteroids or other contributing medications were administered. Blood glucose normalized spontaneously approximately 36 hours after the last capivasertib dose, and all insulin was weaned and discontinued by 26 April 2025. She remained euglycemic without antidiabetic therapy thereafter. The patient and family opted for palliative care, and she passed away on 6 May 2025.

CONCLUSION

Capivasertib can precipitate severe, insulin-resistant hyperglycemia even in non-diabetic patients, without progression to overt hyperglycemic crisis. Spontaneous resolution upon drug cessation supports a direct drug-mediated mechanism via AKT-disrupted insulin signaling. Clinicians should monitor glucose closely during therapy and consider drug cessation in refractory cases. Further studies are warranted to guide optimal glycemic management.

EP_A059

THE VARIABLE NATURE OF BIOPSY-PROVEN VILDAGLIPTIN-INDUCED BULLOUS PEMPHIGOID IN AN ELDERLY PATIENT: A CASE SERIES

Mohd Fyzal Bahrudin¹, Chin Voon Tong¹, Raja Nurazni Raja Azwan¹, Hazleen Zainal², Zanariah Hussein¹

¹Institut Endokrin, Hospital Putrajaya

²Unit Dermatologi, Hospital Putrajaya

INTRODUCTION

Bullous pemphigoid (BP) is the most common autoimmune blistering disease. Drug-induced BP has been increasingly reported, with dipeptidyl peptidase-4 (DPP-4) inhibitors, particularly vildagliptin, emerging as a notable cause. The pathogenesis is thought to involve the disruption of immune tolerance and epitope spreading, leading to a broader autoimmune response against basement membrane antigens beyond the classic NC16A domain of BP180. This case series highlights the variable clinical spectrum and therapeutic challenges in vildagliptin-induced BP.

CASES

A 74-year-old male with type 2 diabetes mellitus (T2DM), hypertension, dyslipidemia, and a history of stroke presented with a 2-month history of recurrent, pruritic, tense bullae. He had been on vildagliptin for 36 months. Histopathology confirmed subepidermal blistering, and direct immunofluorescence demonstrated linear IgG/C3 deposition at the dermo-epidermal junction, with positive anti-BP180 antibodies, diagnosing BP. Discontinuation of vildagliptin and initiation of systemic corticosteroids resulted in significant clinical improvement, allowing a rapid prednisolone taper to 5 mg daily without new bullae formation.

A 62-year-old female with T2DM and dyslipidemia presented with bullous eruptions 3 months after initiating vildagliptin. Skin biopsy confirmed BP, revealing subepidermal blistering with eosinophils and linear C3/IgG deposition at the basement membrane zone. Vildagliptin